JRW 0590

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of

Docket No: Q90951

Hideaki SHIMADA, et al.

Appln. No.: 10/554,026

Group Art Unit: Unassigned

Confirmation No.: 1874

Examiner: Unassigned

Filed: October 21, 2005

For:

APOPTOSIS-INDUCING AGENT AND METHOD FOR INDUCING APOPTOSIS

SUBMISSION OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT (IPER)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For the Examiner's convenience, enclosed herewith is a copy of the International Preliminary Examination Report (IPER). It is noted that all of the references identified in the IPER were previously listed on a PTO/SB/08 A & B when a copy of the International Search Report was submitted on October 21, 2005.

Respectfully submitted,

Registration No. 32,607

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 29, 2006

RECEIVED

with thanks

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICA'FION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

HIRAKI, Yusuke
Kamiya-cho MT Building, 19F, 3-20
Toranomon 4-chome
Minato-ku Tokyo 105-0001
JAPON

MAR. 3 0. 2006

Date of mailing (day/month/year)
09 March 2006 (09.03.2006)

Applicant's or agent's file reference PH-2082-PCT

International application No. PCT/JP2004/004516

IMPORTANT NOTIFICATION

International filing date (day/month/year) 30 March 2004 (30.03.2004)

Applicant

JAPAN SCIENCE AND TECHNOLOGY AGENCY et al

١.	Transmittal	of the	translation	to	the a	pplicant.
----	-------------	--------	-------------	----	-------	-----------

✓	The International Bureau transmits herewith a copy	of the English translation of the international preliminary report	211
لــنا	patentability (Chapter I).	•	

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer

Yoshiko Kuwahara

Facsimile No.+41 22 338 90 90

Facsimile No.+41 22 740 14 35

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference PH-2082-PCT	FOR FURTHER ACTION	See item 4 helow	
International application No. PCT/JP2004/004516	International filing date (day/month/year) 30 March 2004 (30.03.2004)	Priority date (day/month/year) 21 April 2003 (21.04.2003)	
International Patent Classification (8th See relevant information in Form F	n edition unless older edition indicated) PCT/ISA/237		
Applicant JAPAN SCIENCE AND TECHNOL	OGY AGENCY		

1.	This international preliminary International Searching Author	report on patentability (Chapter I) is issued by the International Bureau on behalf of the rity under Rule 44 bis.1(a).
2.	This REPORT consists of a tot	tal of 7 sheets, including this cover sheet.
	In the attached sheets, any refe to the international preliminary	rence to the written opinion of the International Searching Authority should be read as a reference report on patentability (Chapter I) instead.
3.	This report contains indication	s relating to the following items:
	Box No. I	Basis of the report
	Box No. II	Priority
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	Box No. IV	Lack of unity of invention
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	Box No. VI	Certain documents cited
	Box No. VΠ	Certain defects in the international application
	Box No. VΠΙ	Certain observations on the international application
4.	The International Bureau will onot, except where the applicant date (Rule 44bis .2).	communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority
		Date of issuance of this report

	Date of issuance of this report 02 March 2006 (02.03.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Yoshiko Kuwahara
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 90 90

PATENT COOPERATION TREATY

From t	the RNATTONAL SEARCH	ING AUTHOR	RITY		and the second
l'o:					PCT PCT
					RITTEN OPINION OF THE IONAL SEARCHING AUTHORITY
					(PCT Rule 43his.1)
				Date of mailing (day/month/year)	· · · · · · · · · · · · · · · · · · ·
Applic	cant's or agent's file refere	nce		FOR FURTHER	ACTION
PH-	-2082-PCT				See paragraph 2 below
Interna	ational application No.		International filing date	(day/month/year)	Priority date (day/month/year)
PC:	r/JP2004/004	1516	30.03.2004		21.04.2003
Applic JAI		AND TEC	CHNOLOGY AGE	NCY	
	The second secon				
1.			ing to the following items	s.	
	Box No. I	Basis of the	opinion		
	Box No. II	Priority			
	Box No. III	Non-establis	shment of opinion with reg	gard to novelty, inventi	ve step and industrial applicability
	Box No. IV	Lack of unit	y of invention		
	Box No. V		atement under Rule 43bis. ; citations and explanation		ovelty, inventive step or industrial ement
	Box No. VI	Certain docu	ments cited		
	Box No. VII	Certain defe	cts in the international app	plication	
	Box No. VIII	Certain obse	rvations on the internation	nal application	
2.	FURTHER ACTION	•			
<u>-</u> .	If a demand for intelline International Prelimina than this one to be the	rnational prelin ary Examining A IPEA and the o	Authority ("IPEA") excep	that this does not app the International Bure	be considered to be a written opinion of the ly where the applicant chooses an Authority other au under Rule $66.1bis(b)$ that written opinions of
	written reply together.	where appropr	considered to be a writter riate, with aniendments, of 22 nionths from the pri	before the expiration	, the applicant is invited to submit to the IPEA a of 3 months from the date of mailing of Form spires later.
	For further options, see	Form PCT/ISA	/ 220.		
3.	For further details, see	notes to Form P	C17/ISA/220.		
Vianus a	nd mailing address of the	ISA/IP		Authorized officer	
vame ai	no marting address of the	. ISAVIT		Admonized officer	
. ,	1- 11			Talanhora No	,

International application No.
PCT/JP2004/004516

Box	x No. 1 Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
	This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
	a. type of material
	a sequence listing
	table(s) related to the sequence listing
	b. format of material
	in written format
	in computer readable form
	c. time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:

International application No.

PCT/JP2004/004516

Box No. 1	Non-establishment of opini	on with regard to novelty, inventive step and industrial applicability
The quest	ions whether the claimed invention a have not been examined in respect of:	appears to be novel, to involve an inventive step (to be non obvious), or to be industrially
	the entire international application	
\boxtimes	claims Nos. 8-14	
becaus	se:	
\boxtimes	the said international application, or t	he said claims Nos. 8–14
	relate to the following subject matter	which does not require an international preliminary examination (specify):
	Claims 8-14 relate	to methods for treatment of the human body by therapy.
	the description, claims or drawings (i are so unclear that no meaningful opi	ndicate particular elements below) or said claims Nos. nion could be formed (specify):
_		
	the claims, or said claims Nos. by the description that no meaningful	opinion could be formed.
\boxtimes	no international search report has bee	n established for said claims Nos. 8-14
	the nucleotide and/or amino acid seq Instructions in that:	uence listing does not comply with the standard provided for in Annex C of the Administrative
	the written form	has not been furnished
		does not comply with the standard
	the computer readable form	has not been furnished
	•	does not comply with the standard
	the tables related to the nucleotide a technical requirements provided for it	nd/or amino acid sequence listing, if in computer readable form only, do not comply with the a Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further det	nils.

International application No.
. PCT/JP2004/004516

Box			ule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; pporting such statement	
1.	Statement			
	Novelty (N)	Claims	1-7	YES
		Claims		NO
	Inventive step (18)	Claims	1-7	YES
		Claims		NO
	Industrial applicability (IA)	Claims	1-7	YES
		Claims		NO

2. Citations and explanations:

Claims 1-7

Document 1: (J. Liu, et al.), Mol Cell, February 2000, 5 (2): 331-341

Document 2: (J. Liu, et al.), Cell, 9 February, 2001 (09.02.01), 104 (3): 353-363

Document 3: (L. He, et al.), EMBO J., 1 March, 2000 (01.03.00), 19 (5): 1034-1044

None of the documents cited in the ISR describes or suggests that FIR (FUSE binding protein interacting repressor) has an effect of inducing apoptosis.

International application No.

PCT/JP2004/004516

Cena	ain published documents (Rule 43bis. Lai	nd 70.10)			
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/yea	Priority date (va	
	WO 2004/018679 A1 [E, X]	 	22.08.20		
	WO 2004/027061 A1 [E, Y]	01.04.2004	16.09.20	03 17.09.2	200
				·	
		•			
	•				
				•	
Non-v	written disclosures (Rule 43 <i>bis</i> .1 and 70.9	D) .			
Non-v	written disclosures (Rule 43 <i>bis</i> .1 and 70.9 Kind of non-written disclosure	Date of non-written dis (day/month/year		Date of written disclosur ferring to non-written disclo (day/month/year)	
Non-v		Date of non-written dis		ferring to non-written discl	
Non-v		Date of non-written dis		ferring to non-written discl	
Non-v		Date of non-written dis		ferring to non-written discl	
Non-v		Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	
Non-v	Kind of non-written disclosure	Date of non-written dis		ferring to non-written discl	

International application No.

PCT/JP2004/004516

Box No. VIII

Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1, 3 and 5-7

The subject matters of claims 1, 3 and 5-7 relate to an apoptosis-inducing agent having as the active ingredient a protein defined by a desired property as "interacts with FUSE binding proteins". Claims 1, 3 and 5-7 encompass all the proteins that have such property, however, only a limited part of the claimed proteins are disclosed in the sense of PCT Article 5. Therefore, the claims are not supported by the disclosure in the specification in the sense of PCT Article 6.

Even with the common technical knowledge prevailing at the time of filing of the present application, it would have been impossible to define a range of proteins that "interact with FUSE binding proteins". Accordingly, claims 1, 3 and 5-7 do not satisfy the requirement of clarity according to the provisions of PCT Article 6.